In this video, Motley Fool health care analyst Brenton Flynn highlights a couple of emerging trends that medical technology investors should be watching. The first thing he has his eye on is a new procedure called renal denervation, a method to treat patients with hypertension who don't respond to medication. His second area to watch is how different pharmaceutical and biotech companies push into emerging markets, and how they address the need for more value-oriented solutions in these areas.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.